Eaton continues eMobility expansion in Europe to support EV growth
9.5.2023 13:30:00 EEST | Business Wire | Press release
Intelligent power management company Eaton today announced it is continuing to expand and evolve its European eMobility business design capabilities, technologies and operations to support global electrified vehicle manufacturers. These upgrades will support Eaton’s efforts in delivering electric vehicle solutions to passenger car, commercial vehicle and off-highway OEMs globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509005268/en/
Eaton leaders, including Pete Denk, president, Vehicle Group, Eaton (left), Krzysztof Kaszkur, manufacturing manager, eMobility, Eaton (center), and Benito Dominguez, director, Operations, eMobility, Eaton (right), tour the new eMobility manufacturing line at the Vehicle Group’s Tczew, Poland, facility. (Photo: Business Wire)
“The electrification of automotive and commercial vehicle markets requires new capabilities to meet the changing industry,” said Mark Schneider, president, eMobility, Eaton. “We are seeing increasing global demand for electrified vehicle solutions that are designed and produced in our European locations.”
Montrottier producing power electronics components for global EV manufacturers
Eaton’s eMobility business has invested in a state-of-the-art production facility for power electronics components in Montrottier, France. High-volume production is scheduled to begin in mid-2023. The power electronics technologies leverage Eaton’s expertise in managing high-voltage power, resulting in advanced vehicle traction inverters and DC/DC converters with a focus on power density and efficiency.
Tczew facility adding eMobility production
Eaton this year also expanded a current site in Tczew, Poland, to include electrified vehicle capabilities to meet the demand of European and global customers. The transformation of the facility was marked with a celebration for the plant employees, company leadership and government representatives.
“The addition of eMobility products to one of our premier facilities reflects Eaton’s ability to provide its customers the solutions they need during the transition from traditional internal combustion engine vehicles to electrified powertrains,” Schneider said.
Bonn facility designed award-winning Breaktor circuit protection technology
Eaton’s site in Bonn, Germany, has been a sophisticated electrical engineering design and testing facility for many years, focusing on industrial controls and protection and power distribution. The Bonn team is leveraging this electrical expertise and capabilities and applying it to electric vehicle systems with the design of the Breaktor® circuit protection technology – leapfrogging EV circuit protection solutions currently on the market.
This new circuit protection solution was named “Best Technology” in the Electrification category at the Hyundai-Kia Motors Corporation’s annual R&D Partners Tech Day. The recognition follows other recent accolades for Eaton’s Breaktor circuit protection technology, including an Automotive News PACEpilot award and the Gasgoo Award 2022 – Top 100 Players of China’s New Automotive Supply Chain in the powertrain electrification segment.
New site in Karlsruhe, Germany, serves as a base for customer interaction and engineering service
Eaton last year established a new office and laboratory facility in Karlsruhe that contains multiple workstations and a laboratory. Due to its proximity to major manufacturers and suppliers, the new office serves as a base for customer interaction and engineering services in the region. It will soon feature a brand-new innovation and testing lab for the testing of power electronics and power distribution products, enabling rapid turnaround in testing of the latest eMobility products. Eaton also is expanding eMobility production in Gummersbach, Germany, and Györ, Hungary, by leveraging Eaton’s Electrical Sector manufacturing facilities.
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.
Founded in 1911, Eaton is marking its 100th anniversary of being listed on the New York Stock Exchange. We reported revenues of $20.8 billion in 2022 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005268/en/
Contact information
Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom